
Brian Goff, Agios CEO
Agios' late-stage Pyrukynd trial in kids with rare blood disorder misses primary endpoint
Agios’ first-ever pediatric data readout missed the primary endpoint, with its drug Pyrukynd (mitapivat) not showing statistical significance in children with pyruvate kinase (PK) deficiency …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.